Even though the blood sugar levels are under control in patients with type 1 diabetes (T1D), they may experience "glycemic excursions", (blood sugar levels changing from high levels to low levels) with insulin. A study shows a marked reduction in blood sugar levels in most of the patients with type 1 diabetes (T1D) with dapagliflozin. Currently, dapagliflozin was being used to treat patients with type 2 diabetes (T2D).
Researchers have conducted a 24 week study (in 17 countries including the United States) named as the "Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes Study" (DEPICT-1), to find out the drug efficacy and safety as an adjunct treatment for insulin in patients with type 1 diabetes (T1D) with inadequately controlled blood glucose levels. The total number of the participants in the first Phase 3 trial was 833, aged between 18 and 75 years.
The study results show about 50 percent of the patients with type 1 diabetes (T1D) have successfully reduced their A1C levels by more than 0.5 percent without hypoglycemia (low blood sugar levels). The authors say that the dapagliflozin is eligible for approval by the United States FDA as an antidiabetic agent for patients with type 1 diabetes (T1D) as the drug reduces HbA1c levels by about 0.5 percent. But they say the drug needs further studies to confirm the current study.
This study was funded by Bristol-Myers Squibb and AstraZeneca, development partners of dapagliflozin. Manufacturers likely to apply for United States FDA approval after the 56-week DEPICT-1 study and DEPICT-2 (a parallel study of dapagliflozin). Senior author of the study was Professor Paresh Dandona, MD, Ph.D., chief of endocrinology, diabetes and metabolism, Jacobs School of Medicine and Biomedical Sciences, the University at Buffalo.
9. MonoPepT1De trial shows a slowdown in the development of type 1 diabetes with a retrained immune system
10. A cure for Type 1 Diabetes (T1D) With Gene Transfer Technique
A study by researchers at the Institute of Environmental Medicine (IMM), Karolinska Institutet, Sweden shows twice likely risk of the development of diabetes, apart from the risk of high blood pressure (BP or hypertension) among those people who consume more salt (as 40 percent of salt is sodium). Researchers say salt directly affects insulin resistance.
The study results show 43 percent increased risk for the development of type 2 diabetes (T2D) with 2.5 grams of extra salt consumption (equal to one gram of sodium) per day. The study also shows 72 percent of increased risk for the development of type 2 diabetes (T2D) in individuals who consume more than 7.3 grams of salt per day when compared with individuals who consume less than six grams of salt per day.
Individuals with human leukocyte antigen (HLA) and consuming high amounts of salt (more than 3.15 grams of salt per day) are at four times higher risk of the development of type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) compared with individuals consuming low amounts of salt (less than 2.4 grams of salt per day).
Lead author of the study was Bahareh Rasouli, the Institute of Environmental Medicine (IMM). The study was presented at the annual meeting of the European Association for the Study of Diabetes (EASD) 2017, Lisbon, Portugal and published on September 14, 2017, in the Diabetologia. Title of the article was "Sodium (salt) intake is associated with a risk of developing type 2 diabetes."
9. Enhanced risk for celiac disease in type 1 diabetes in children
10. Limit Consumption Of Salt, Sugar And Saturated Fat To Keep Good Heart Health
Type 1.5 diabetes : Type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) is a type 1 diabetes (T1D) which appears during adulthood. The onset of LADA in adulthood is slower when compared to the onset of type 1 diabetes (T1D) in childhood. This occurs due to the destruction or damage to the insulin-producing beta cells in the pancreas.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.